Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. [electronic resource]
Producer: 20140124Description: 363-7 p. digitalISSN:- 1423-0240
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab
- Camptothecin -- administration & dosage
- Capecitabine
- Colorectal Neoplasms -- drug therapy
- Comorbidity
- Deoxycytidine -- administration & dosage
- Drug-Related Side Effects and Adverse Reactions -- mortality
- Evidence-Based Medicine
- Female
- Fluorouracil -- administration & dosage
- Humans
- Irinotecan
- Male
- Middle Aged
- Prognosis
- Risk Factors
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.